Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment
integer.net

See what CB Insights has to offer

Investments

5

Portfolio Exits

3

Partners & Customers

6

Service Providers

2

About Integer

Integer (NYSE:ITGR) is a medical device outsource (MDO) manufacturer serving the cardiac, neuromodulation, vascular and portable medical markets. The company provides technologies and manufacturing to Medical Device OEM’s to enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. Greatbatch Medical®, Lake Region Medical® and Electrochem® comprise the company’s brands.

Integer Headquarter Location

2591 Dallas Parkway Suite 101

Frisco, Texas, 75034,

United States

716-659-5600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Integer

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Integer in 3 Expert Collections, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

B

Bioelectronics

843 items

Companies developing/using technology aimed at detecting, interpreting, interrupting, eliciting, or redirecting electrical signals within the body

M

Medical Devices

3,718 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Integer Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Integer Rank

Latest Integer News

Stroke management Market revenue to cross USD 48.5 Bn by 2027: Global Market Insights Inc.

Sep 15, 2021

Selbyville, Delaware, Sept. 15, 2021 (GLOBE NEWSWIRE) -- According to latest report “Stroke management Market by Type (Ischemic, Hemorrhagic, Transient Ischemic Attack {TIA}), Product (Diagnostic Devices, Therapeutic Devices), End-use (Hospitals, Ambulatory Surgery Centers, Diagnostic Centers), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027”, by Global Market Insights Inc., the market valuation of stroke management will cross $48.5 billion by 2027. High disease prevalence contributing to the demand for interventional treatments will boost the market growth. Technological advancements have led to launch of advanced and efficient products for stroke management. Companies operating in the industry are focusing on reducing procedural complications and offer ease in complex operations with their products. For instance, Cerenovus announced the launch of Cerenovus Nimbus in Europe. The device is designed with two different design features for maximization of tough clot removal including a proximal spiral section and distal barrel section. Such developments will foster the product adoption rate and will accelerate the demand. Moreover, healthcare providers are also collaborating and partnering with industry leaders to advance their stroke management capabilities. Recently, Apollo Hospitals and Medtronic partnered to integrate AI platform in stroke management that will reduce the diagnosis period. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/3550 Growing disease burden of cardiovascular diseases (CVD) across the globe will significantly influence the stroke management market progression. Rising prevalence of heart diseases including coronary artery disease increases the possibilities of plaque formation in arteries that blocks the flow of oxygen-rich blood to the brain. Such conditions increase the risk of stroke and related mortalities. Additionally, causative factors contributing to CVD such as high blood pressure and blood glucose levels are considered as potential causes for stroke. Further, geriatric population prone to cardiovascular diseases will drive the product demand in the coming years. Transient ischemic attack (TIA) segment in the stroke management market accounted for USD 700 million in 2020. Transient ischemic attack (TIA) is ministroke caused attributed to temporary disruption in the blood supply to part of the brain. Increasing geriatric population globally is one of the major factors stimulating the industry growth. Geriatric population is more susceptible to transient ischemic attack and requires effective medical care to maintain health condition. The stroke management market for diagnostic devices segment will witness 5.9% growth rate through 2027. Growing advancement in diagnostics techniques such as visualization software, open MRI, and others. This advancement simplifies imaging workflow and faster scanning. For instance, In September 2016, GE Healthcare’s received U.S. FDA approval for its MAGiC (MAGnetic resonance image Compilation) software that is used for diagnosis and management of acute ischemic stroke. Diagnostic centers segment is estimated to attain a CAGR of 6.3% till 2027. Growing preference of patients suffering from several cardiovascular diseases towards diagnostics centers due to presence of medical professional and facilities. Adding to this, growing demand for stroke management devices in hemorrhage, ischemia and emergency cases will propel the segment growth. Asia Pacific stroke management market is poised to expand at over 6.6% CAGR by 2027 owing to the increasing prevalence of acute ischemic stroke coupled with rising demand for minimally invasive procedures. According to the OECD, ischemic stroke was one of the major causes of death in APAC in 2016, accounting for 25.2% of all deaths in the Western Pacific and 34.8% of deaths in Southeast Asia region. Adding to this, growing prevalence of cardiovascular diseases along with several initiatives undertaken by government in development of healthcare facilities will further contribute to the regional growth. Request for customization of this research report @ Major players operating in the stroke management market include Abbott, Asahi Intecc CO., LTD, Braun Melsungen AG, Boston Scientific Corporation, GE Healthcare, Integer Holdings Corporation, Johnson & Johnson and Medtronic among others. Industry leaders are implementing various strategies such as new product launches and acquisitions & mergers to gain competitive advantage for business expansion. The providers are constantly adopting new techniques to offer advanced devices. Table of Contents (ToC) of the report: Chapter 3   Stroke management Market Insights 3.1    Industry segmentation 3.3    Industry impact forces

Integer Investments

5 Investments

Integer has made 5 investments. Their latest investment was in Aleva Neurotherapeutics as part of their Series D on October 10, 2017.

CBI Logo

Integer Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/4/2017

Series D

Aleva Neurotherapeutics

$13M

No

1

5/27/2016

Series C

Subscribe to see more

$99M

Subscribe to see more

10

10/16/2015

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/12/2008

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/4/2017

5/27/2016

10/16/2015

11/12/2008

Round

Series D

Series C

Series A

Series B

Other Investors

Company

Aleva Neurotherapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$13M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Integer Portfolio Exits

3 Portfolio Exits

Integer has 3 portfolio exits. Their latest portfolio exit was Integer - Advanced Surgical and Orthopedics Product Lines on May 03, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/3/2018

Divestiture

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

5/3/2018

00/00/0000

00/00/0000

Exit

Divestiture

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Integer Acquisitions

10 Acquisitions

Integer acquired 10 companies. Their latest acquisition was Inomec on February 19, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/19/2020

Acquired

1

10/8/2019

$991

Acquired

3

3/14/2016

IPO

Spinoff / Spinout

1

8/27/2015

Acquired

Subscribe to see more

$991

$99M

Subscribe to see more

10

8/13/2014

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/19/2020

10/8/2019

3/14/2016

8/27/2015

8/13/2014

Investment Stage

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$99M

$99M

Note

Acquired

Acquired

Spinoff / Spinout

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

Integer Partners & Customers

6 Partners and customers

Integer has 6 strategic partners and customers. Integer recently partnered with Respicardia on January 1, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

1/14/2019

Client

Respicardia

United States

Integer Supports Respicardia’s Commercialization in the Central Sleep Apnea Market through Two New Agreements

14 , 2019 -- Integer Holdings Corporation , a leading medical device outsource manufacturer , today announced it has entered into a new development agreement and a new supply agreement with Respicardia , Inc. , a medical technology company dedicated to developing innovative therapies that address unmet needs in respiratory and cardiovascular disease .

1

1/18/2018

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

12/8/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

1/5/2016

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

8/26/2015

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

1/14/2019

1/18/2018

12/8/2016

1/5/2016

8/26/2015

Type

Client

Partner

Partner

Licensor

Partner

Business Partner

Respicardia

Country

United States

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Integer Supports Respicardia’s Commercialization in the Central Sleep Apnea Market through Two New Agreements

14 , 2019 -- Integer Holdings Corporation , a leading medical device outsource manufacturer , today announced it has entered into a new development agreement and a new supply agreement with Respicardia , Inc. , a medical technology company dedicated to developing innovative therapies that address unmet needs in respiratory and cardiovascular disease .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Integer Service Providers

2 Service Providers

Integer has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired - II

Investment Bank

Joint Bookrunner, Joint Lead Arranger

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acquired - II

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Joint Bookrunner, Joint Lead Arranger

Subscribe to see more

Partnership data by VentureSource

Integer Team

7 Team Members

Integer has 7 team members, including former Chief Executive Officer, Ricky Gold.

Name

Work History

Title

Status

Ricky Gold

Chief Executive Officer

Former

Thomas Hook

Chief Executive Officer

Former

Jeremy Friedman

President, Chief Financial Officer, Chief Operating Officer, Executive Vice President

Former

George Cintra

Chief Technology Officer, Executive Vice President

Former

Andrew Holman

Chief Commercial Officer

Former

Name

Ricky Gold

Thomas Hook

Jeremy Friedman

George Cintra

Andrew Holman

Work History

Title

Chief Executive Officer

Chief Executive Officer

President, Chief Financial Officer, Chief Operating Officer, Executive Vice President

Chief Technology Officer, Executive Vice President

Chief Commercial Officer

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.